TELMISARTAN 40mg. IP + AMLODIPINE 5mg. IP

A single-pill combination of an angiotensin II receptor antagonist, and a dihydropyridine calcium channel antagonist for the treatment of hypertension. (Moen, 2010) Demonstrates effectiveness in the reduction in systolic BP (SBP) as well as diastolic BP (DBP) in stage II hypertensive patients. (Faruqui, 2008) An effective and well-tolerated treatment as initial therapy for patients likely to require > 1 antihypertensive agent to reach BP targets. (Guthrie, 2011) Significantly decreases the blood pressure in patients whose hypertension was not controlled by 5 mg of amlodipine. (Mitsuru Ohishi, 2013) A safe efficacious option for the long-term treatment of hypertension. (Marcovitz, 2013) Shows significantly greater reductions in BP than telmisartan or amlodipine monotherapy. (Moen, 2010) A beneficial therapeutic choice in the management of patients with hypertension. (M Sharpe, 2001) Offers a substantial and sustained 24-h BP-lowering effect in a range of patients with hypertension, who are at risk for cardiovascular events. (K Ahrens, 2010) An attractive choice for difficult-to-control hypertensive patients at cardiovascular risk, including those with diabetes, or those who are obese, elderly, not controlled by amlodipine monotherapy, or who are intolerant to angiotensin-converting enzyme inhibitors. (K Ahrens, 2010)